Chronic Myeloid Leukemia News

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML

For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.

Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML

Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML

Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

Previous studies have shown that first-line therapy with nilotinib, as well as switching to nilotinib after prolonged imatinib, may lead to higher rates of deep molecular response in chronic myeloid leukemia.

Deep Molecular Response May Allow TKI-therapy Discontinuation in Chronic Myeloid Leukemia

Deep Molecular Response May Allow TKI-therapy Discontinuation in Chronic Myeloid Leukemia

Targeted therapies among patients with chronic myeloid leukemia have improved over time, leading to patients achieving high rates of deep molecular response — a prerequisite criteria for tyrosine kinase inhibitor discontinuation.

Low-dose Dasatinib May Be Effective as Frontline Therapy in Chronic-phase Chronic Myeloid Leukemia

Low-dose Dasatinib May Be Effective as Frontline Therapy in Chronic-phase Chronic Myeloid Leukemia

Dasatinib 100 mg is currently approved for chronic myeloid leukemia but has been associated with high rates of adverse events.

FDA Approves Nilotinib for Pediatric Patients With CML

FDA Approves Nilotinib for Pediatric Patients With CML

Patients one year or older are now eligible to receive the drug.

Ivermectin Induces Apoptosis Through Mitochondrial Dysfunction in CML Cells

Ivermectin Induces Apoptosis Through Mitochondrial Dysfunction in CML Cells

A recent study sought to determine the effect of ivermectin against CML cells, whether ivermectin can sensitize cells to BCR-ABL TKIs, and its mechanism of action.

Molecular Response and Sokal Score Associated with Treatment-free Remission Duration in CML

Molecular Response and Sokal Score Associated with Treatment-free Remission Duration in CML

A subset of patients with chronic-phase CML in the ENESTfreedom study maintained treatment-free remission for at least 96 weeks after being treatment with frontline nilotinib.

Patients with Chronic Myeloid Leukemia at Increased Risk of Secondary Cancers

Patients with Chronic Myeloid Leukemia at Increased Risk of Secondary Cancers

Recently published findings suggest that patients with CML, particularly men, have a 30% higher risk of developing secondary cancers; however the cause of this increased risk is unclear.

Dasatinib: A Safe and Effective Option for Pediatric CML

Dasatinib: A Safe and Effective Option for Pediatric CML

Previous studies have shown that dasatinib may be an effective therapeutic alternative to imatinib.

Pediatric CML: Imatinib Effective in the Front Line

Pediatric CML: Imatinib Effective in the Front Line

Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.

FDA Approves Bosutinib for Newly Diagnosed Chronic Myeloid Leukemia

FDA Approves Bosutinib for Newly Diagnosed Chronic Myeloid Leukemia

Approval was based on results from the randomized phase 3 BFORE trial, which showed a higher MMR rate in patients treated with bosutinib than in those treated with imatinib.

Radioactive Iodine Increases Risk of AML, CML in Patients With Thyroid Cancer

Radioactive Iodine Increases Risk of AML, CML in Patients With Thyroid Cancer

The risk of AML decreased after 2 years, returning to baseline within 6 years of WDTC diagnosis, but the risk of CML remained elevated for up to 10 years.

Nilotinib Dose, Frequency Reduction Maintains Efficacy in Chronic Myeloid Leukemia

Nilotinib Dose, Frequency Reduction Maintains Efficacy in Chronic Myeloid Leukemia

Researchers analyzed the outcomes of 67 patients with BCR-ABL1-positive CML in chronic phase who had an MMR on nilotinib twice daily and who then switched to a once-daily reduced-dose regimen.

Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia

Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia

Researchers randomly assigned 241 patients to receive radotinib 300 mg twice daily, radotinib 400 mg twice daily, or imatinib 400 mg once daily.

Imatinib Effective as Front-line Therapy for Pediatric Chronic Myeloid Leukemia

Imatinib Effective as Front-line Therapy for Pediatric Chronic Myeloid Leukemia

Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.

Inotuzumab Ozogamicin Plus Bosutinib May Be Safe, Effective for Relapsed/Refractory ALL and CML

Inotuzumab Ozogamicin Plus Bosutinib May Be Safe, Effective for Relapsed/Refractory ALL and CML

Eleven patients had a complete response: 10 had complete cytogenic remission, 8 were negative by flow cytometry, 6 had undetectable BCR-ABL. Three patients did not respond.

FDA Approves Dasatinib for Pediatric Philadelphia Chromosome-positive CML

FDA Approves Dasatinib for Pediatric Philadelphia Chromosome-positive CML

The FDA based its approval on results from 2 ongoing clinical studies: the open-label, prospective CA180-226 phase 2 trial, and the dose-ranging CA180-018 phase 1 trial.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs